SOD1 and in situ carcinoma: Treatment with CIS resulted in a significant increase in MDA levels (~5.3-fold) and a significant decrease in GSH (~5.7-fold), SOD (~2.5-fold), and GPx (~3.1-fold) levels compared to control.